Document:

EX-4.5

 Exhibit 4.5 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE
SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND
SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 WARRANT TO PURCHASE
STOCK 
  

			
	Company:	  	HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation
	Number of Shares:	  	1,256,281 (Subject to Section 1.7)
	Type/Series of Stock:	  	Series E Preferred (Subject to Section 1.7)
	Warrant Price:	  	$0.2189 per share (Subject to Section 1.7)
	Issue Date:	  	August 22, 2014
	Expiration Date:	  	August 22, 2024 See also Section 5.1(b).
	Credit Facility:	  	This Warrant to Purchase Stock (“Warrant”) is issued in connection with that certain Loan and Security Agreement of even date herewith among Oxford Finance LLC, as Lender and Collateral Agent, the Lenders from time
to time party thereto, including Silicon Valley Bank and the Company (as modified, amended and/or restated from time to time, the “Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, OXFORD FINANCE LLC
(“Oxford” and, together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and
non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”) of the above-named company (the “Company”) at the above-stated Warrant Price, all as set forth above and
as adjusted pursuant to Sections 1.7 and 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. 

SECTION 1. EXERCISE. 
 1.1
Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form
attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment
acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. 
 1.2 Cashless Exercise. On any exercise
of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of
this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula: 

 

					
		 	X = Y(A-B)/A
			
	where:	 		  	
			
		 	X =	  	the number of Shares to be issued to the Holder;
			
		 	Y =	  	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);

  
 1 

					
			
		 	A =	  	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and
			
		 	B =	  	the Warrant Price.

 1.3 Fair Market Value. If the Company’s common stock is then traded or quoted on a nationally
recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the Class is common stock, the fair market value of a Share shall be the closing price or last sale price of a share
of common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s common stock is then traded in a Trading Market and the Class
is a series of the Company’s convertible preferred stock, the fair market value of a Share shall be the closing price or last sale price of a share of the Company’s common stock reported for the Business Day immediately before the date on
which Holder delivers this Warrant together with its Notice of Exercise to the Company multiplied by the number of shares of the Company’s common stock into which a Share is then convertible. If the Company’s common stock is not traded in
a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment. 

1.4 Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set forth in
Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor
representing the Shares not so acquired. 
 1.5 Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company
of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation,
on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount. 

1.6 Treatment of Warrant Upon Acquisition of Company. 

(a) Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity (other than
a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or
reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders beneficially own a
majority of the outstanding voting power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or other transfer by
the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power. 

(b) Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s
stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), either (i) Holder shall exercise this Warrant pursuant to Section 1.1
and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation of such Acquisition or (ii) if Holder elects not to exercise the Warrant, this Warrant will automatically expire immediately prior
to the consummation of such Acquisition. 
 (c) The Company shall provide Holder with written notice of its request relating to the
Cash/Public Acquisition (together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash/Public Acquisition giving rise to such notice), which is to be
delivered to Holder not less than seven (7) Business Days prior to the closing of the proposed Cash/Public Acquisition. In the event the Company does not provide such notice, then if, immediately prior to the Cash/Public Acquisition, the fair
market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date,

  
 2 

 
then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not
previously have been exercised, and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon such exercise to the Holder and Holder shall be deemed to have restated each of the representations and
warranties in Section 4 of the Warrant as the date thereof. 
 (d) Upon the closing of any Acquisition other than a Cash/Public
Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the
Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this
Warrant. 
 (e) As used in this Warrant, “Marketable Securities” means securities meeting all of the following
requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its
filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to
exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other
securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises solely under
federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition. 

1.7 Adjustment to Class of Shares; Number of Shares; Warrant Price; Adjustments Cumulative. If, upon the closing of the Next Equity
Financing, the Next Equity Financing Price shall be less than the Warrant Price in effect as of immediately prior thereto, then the “Class” shall be Next Equity Financing Securities from and after such closing, subject to adjustment
thereafter from time to time in accordance with the provisions of this Warrant and the “Warrant Price” shall be the Next Equity Financing Price from and after such closing, subject to adjustment thereafter from time to time in accordance
with the provisions of this Warrant; provided, that upon such date, if any, as the “Class” becomes Next Equity Financing Securities pursuant to this sentence, this Warrant shall be exercisable for such number of shares of such Class as
shall equal (i) Two Hundred Seventy-Five Thousand Dollars ($275,000.00) minus the aggregate dollar amount of any previously exercised Shares under this Warrant, divided by (ii) the Next Equity Financing Price, subject to adjustment thereafter
from time to time in accordance with the provisions of this Warrant. As used herein (i) “Next Equity Financing” means the first sale or issuance by the Company on or after the Issue Date of this Warrant set forth above, in a single
transaction or series of related transactions, of shares of its convertible preferred stock or other senior equity securities to one or more investors for cash for financing purposes with proceeds of not less than Two Million Dollars
($2,000,000.00); (ii) “Next Equity Financing Securities” means the type, class and series of convertible preferred stock or other senior equity security sold or issued by the Company in the Next Equity Financing; and
(iii) “Next Equity Financing Price” means the lowest price per share for which Next Equity Financing Securities are sold or issued by the Company in the Next Equity Financing. 

SECTION 2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class
payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property
which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of
shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise,
into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

  
 3 

 2.2 Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all
of the outstanding shares of the Class are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will
be exercisable for the number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in
accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. 

2.3 Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible preferred stock, in the event
that all outstanding shares of the Class are converted, automatically or by action of the holders thereof, into common stock pursuant to the provisions of the Company’s Amended and Restated Certificate of Incorporation (as may be amended from
time to time, the “Charter”), including, without limitation, in connection with the Company’s initial, underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Act (the
“IPO”), then from and after the date on which all outstanding shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common stock into which the Shares would have been converted
had the Shares been outstanding on the date of such conversion, and the Warrant Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares of common stock into which one Share would have
been converted, all subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. 
 2.4
Adjustments for Diluting Issuances. Without duplication of any adjustment otherwise provided for in this Section 2, the number of shares of common stock issuable upon conversion of the Shares shall be subject to anti-dilution adjustment
from time to time in the manner set forth in the Charter as if the Shares were issued and outstanding on and as of the date of any such required adjustment. 

2.5 No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the
fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price. 

2.6 Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company, at the
Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request
from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment. 

SECTION 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows: 

(a) The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of the
Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $500,000 of such shares were sold. 

(b) All Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of the Shares,
shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws. The
Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class, common stock and other securities as will be sufficient to permit the exercise
in full of this Warrant and the conversion of the Shares into common stock or such other securities. 

  
 4 

 (c) The Company’s capitalization table attached hereto as Schedule 1 is true and complete,
in all material respects, as of the Issue Date. 
 3.2 Notice of Certain Events. If the Company proposes at any time to: 

(a) declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property, stock, or other
securities and whether or not a regular cash dividend; 
 (b) offer for subscription or sale pro rata to the holders of the outstanding
shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights); 

(c) effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
Class; 
 (d) effect an Acquisition or to liquidate, dissolve or wind up; or 

(e) effect an IPO; 
 then, in connection with
each such event, the Company shall give Holder: 
 (1) at least seven (7) Business Days prior written notice of the date on which a
record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled thereto) or for determining rights to vote, if any, in respect of the
matters referred to in (a) and (b) above; 
 (2) in the case of the matters referred to in (c) and (d) above at least
seven (7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to exchange their shares for the securities or other
property deliverable upon the occurrence of such event); and 
 (3) with respect to the IPO, at least seven (7) Business Days prior
written notice of the date on which the Company proposes to file its public registration statement in connection therewith. 
 Reference is made to
Section 1.6(c) whereby this Warrant will be deemed to be exercised pursuant to Section 1.2 hereof if the Company does not give written notice to Holder of a Cash/Public Acquisition as required by the terms hereof. Company will also provide
information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements. 

SECTION 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. 

The Holder represents and warrants to the Company as follows: 

4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired
for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring
this Warrant or the Shares. 
 4.2 Disclosure of Information. Holder is aware of the Company’s business affairs and financial
condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has
had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such
information or could acquire it without 

  
 5 

 
unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3 Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such
knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the
Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the
Act. 
 4.5 The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under
the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued
upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is
aware of the provisions of Rule 144 promulgated under the Act. 
 4.6 Market Stand-off Agreement. The Holder agrees that the
Shares shall be subject to the Market Standoff provisions in Section 5.12 of the Company’s Amended and Restated Investor Rights Agreement, dated as of February 4, 2014, as may be amended from time to time or similar agreement. 

4.7 No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant. 

SECTION 5. MISCELLANEOUS. 

5.1 Term; Automatic Cashless Exercise Upon Expiration. 

(a) Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from
time to time on or before 6:00 PM, Eastern time, on the Expiration Date and shall be void thereafter. 
 (b) Automatic Cashless Exercise
upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in
effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the
Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder. 

5.2 Legends. Each certificate evidencing Shares (and each certificate evidencing the securities issued upon conversion of any Shares,
if any) shall be imprinted with a legend in substantially the following form: 
 THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO OXFORD FINANCE LLC DATED

  
 6 

 
AUGUST     , 2014, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM
AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 5.3 Compliance
with Securities Laws on Transfer. This Warrant and the Shares issued upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in
part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the
Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to an affiliate of Holder, provided that any such transferee is an “accredited investor” as defined
in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. 

5.4 Transfer Procedure. After receipt by Oxford of the executed Warrant, Oxford may transfer all or part of this Warrant to one or more
of Oxford’s affiliates (each, an “Oxford Affiliate”), by execution of an Assignment substantially in the form of Appendix 2. Subject to the provisions of Section 5.3 and upon providing the Company with written notice,
Oxford, any such Oxford Affiliate and any subsequent Holder, may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the Shares issuable directly or indirectly, upon conversion of the Shares, if any) to any
other transferee, provided, however, in connection with any such transfer, the Oxford Affiliate(s) or any subsequent Holder will give the Company notice of the portion of the Warrant or Shares being transferred with the name, address and taxpayer
identification number of the transferee and Holder will surrender this Warrant or any Share certificate to the Company for reissuance to the transferee(s) (and Holder if applicable). Notwithstanding any contrary provision herein, at all times prior
to the IPO, Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares
issued upon any exercise hereof, to any person or entity who directly competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor. 

5.5 Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered
and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and
such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or
Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company receives notice of a change of
address in connection with a transfer or otherwise: 
 Oxford Finance LLC 

133 N. Fairfax Street 

Alexandria, VA 22314 
 Attn:
Legal Department 
 Telephone: (703) 519-4900 

Facsimile: (703) 519-5225 

Email: LegalDepartment@oxfordfinance.com 

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address: 

HTG Molecular Diagnostics, Inc. 

3430 E. Global Loop 
 Tucson, AZ
85706 
 Attn: Shaun McMeans 

  
 7 

 Telephone: (520) 901-2139 

Facsimile: (520) 547-2837 

Email: smcmeans@htgmolecular.com 

With a copy (which shall not constitute notice) to: 

Cooley LLP 
 4401 Eastgate Mall

 San Diego, CA 92121 
 Attn:
Steven M. Przesmicki 
 Telephone: (858) 550-6070 

Facsimile: (858) 550-6420 

Email: przes@cooley.com 
 5.6
Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against
which enforcement of such change, waiver, discharge or termination is sought. 
 5.7 Attorneys’ Fees. In the event of any
dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

 5.8 Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall
constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.

 5.9 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without
giving effect to its principles regarding conflicts of law. 
 5.10 Headings. The headings in this Warrant are for purposes of
reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. 
 5.11 Business Days.
“Business Day” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed. 
 [Remainder of
page left blank intentionally] 
 [Signature page follows] 

  
 8 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by
their duly authorized representatives effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	HTG MOLECULAR DIAGNOSTICS, INC.
		
	By:	 	 /s/ Shaun McMeans

		
	Name:	 	 Shaun McMeans

		 	(Print)
	Title:	 	 CFO

	
	“HOLDER”
	
	OXFORD FINANCE LLC
		
	By:	 	 /s/ T.A. Lex

		
	Name:	 	 T.A. Lex

		 	(Print)
	Title:	 	 COO

  

[Signature Page to Warrant to Purchase Stock (Oxford Term A)] 

 APPENDIX 1 

NOTICE OF EXERCISE 
 1.
The undersigned Holder hereby exercises its right purchase                  shares of the Common/Series
             Preferred [circle one] Stock of HTG MOLECULAR DIAGNOSTICS, INC. (the “Company”) in accordance with the attached Warrant To Purchase Stock, and tenders payment
of the aggregate Warrant Price for such shares as follows: 
  

	 	[    ]	check in the amount of $         payable to order of the Company enclosed herewith 

  

	 	[    ]	Wire transfer of immediately available funds to the Company’s account 

  

	 	[    ]	Cashless Exercise pursuant to Section 1.2 of the Warrant 

  

	 	[    ]	Other [Describe]
                                        

 2. Please issue a certificate or certificates representing the Shares in the name specified below: 

 

					
	  
	 		 	
	Holder’s Name	 		 	
			
	  
	 		 	
			
	  
	 		 	
	(Address)	 		 	

 3. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof. 
  

			
	HOLDER:
	
	  

		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	Date:	 	  

  
 Appendix 1 

 APPENDIX 2 

ASSIGNMENT 
 For
value received, Oxford Finance LLC hereby sells, assigns and transfers unto 
  

							
		 	Name:	 	[OXFORD TRANSFEREE]	 	
				
		 	Address:	 	  
	 	
				
		 	Tax ID:	 	  
	 	

 that certain Warrant to Purchase Stock issued by HTG MOLECULAR DIAGNOSTICS, INC. (the
“Company”), on August     , 2014 (the “Warrant”) together with all rights, title and interest therein. 
  

									
		 		 		 	OXFORD FINANCE LLC
					
		 		 		 	By:	 	  

					
		 		 		 	Name:	 	  

					
		 		 		 	Title:	 	  

					
	Date:	 	  
	 		 		 	

 By its execution below, and for the benefit of the Company, [OXFORD TRANSFEREE] makes each of the representations and
warranties set forth in Article 4 of the Warrant and agrees to all other provisions of the Warrant as of the date hereof. 
  

									
		 		 		 	[OXFORD TRANSFEREE]
					
		 		 		 	By:	 	  

					
		 		 		 	Name:	 	  

					
		 		 		 	Title:	 	  

  
 Appendix 2 

 SCHEDULE 1 

Company Capitalization Table 

See attached 
  

  
 Schedule 1EX-4.8

 Exhibit 4.8 

HTG MOLECULAR DIAGNOSTICS, INC. 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTOR RIGHTS
AGREEMENT (this “Agreement”) is entered into as of December 22, 2014, by and among HTG MOLECULAR DIAGNOSTICS, INC., a Delaware
corporation (the “Company”), certain holders of common stock, $0.001 par value per share, of the Company (“Common Stock”) listed on Exhibit A-1 hereto (the “Common
Stockholders”) and the holders of Preferred Stock (as defined below) listed on Exhibit A-2 hereto (the “Investors”). The Common Stockholders and the Investors may be referred to herein individually as a
“Stockholder” and collectively as “Stockholders.” 
 RECITALS 

WHEREAS, in connection with the Company’s prior sale of its Series E Convertible Preferred Stock,
the Company and the Stockholders entered into that certain Amended and Restated Investor Rights Agreement dated as of February 4, 2014 (the “Prior Agreement”); and 

WHEREAS, in anticipation of the consummation of the Initial Offering (as defined below), the Company and
the undersigned Stockholders (on behalf of themselves and all other Investors and all Common Stockholders) desire to enter into this Agreement in order to amend and restate the Prior Agreement as set forth herein. 

AGREEMENT 

NOW, THEREFORE, in consideration of the premises and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 SECTION 1. GENERAL. 

1.1 Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby amended and restated in its entirety as set forth
herein, contingent and effective upon the closing of the Initial Offering (the “Effective Time”), and all rights and covenants made under the Prior Agreement (including registration rights and related notice provisions),
contingent and effective upon the Effective Time, are hereby terminated in their entirety and shall have no further force or effect whatsoever; provided, however, that, if the Initial Offering is not completed for any reason by March 31,
2015 (or such later date as consented to by the Requisite Investors (as such term is defined in the Prior Agreement)), or upon the earlier abandonment of the Initial Offering (whether as a result of the determination of the Board of Directors not to
file with the Commission a registration statement for the Initial Offering or the withdrawal by the Company of the registration statement with respect thereto), this Agreement shall be null and void and the Prior Agreement shall remain in full force
and effect. Notwithstanding the foregoing, the obligations, if any, of Novo, Fletcher and MCV (each as defined in the Prior Agreement) in the intention letters dated on or about June 9, 2011 shall remain discharged in full, effective as of
November 2, 2012. 
 1.2 Definitions. As used in this Agreement, the following terms shall have the following respective
meanings: 
 “Affiliate” has the meaning ascribed to that term in Rule 12b-2 under the Exchange Act, or any
successor rule. 
 “Certificate of Incorporation” means the Company’s Amended and Restated Certificate of
Incorporation filed with the Secretary of State of the State of Delaware on February 3, 2014, as amended and/or restated from time to time. 

“Commission” means the Securities and Exchange Commission and any successor agency of the federal government
administering the Securities Act and the Exchange Act. 
 “Exchange Act” means the Securities Exchange Act of 1934,
as amended, and any similar or successor federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect from time to time. 

“Initial Offering” means the Company’s first firm commitment underwritten public offering of its Common Stock
registered under the Securities Act, in connection with which the outstanding shares of Preferred Stock are converted into shares of Common Stock. 

  
 1 

 “Person” or “person” means an individual,
corporation, partnership, limited liability company, joint venture, trust or unincorporated organization, or a government or any agency or political subdivision thereof. 

“Preferred Stock” means the Company’s Series A Convertible Preferred Stock, Series B Convertible Preferred
Stock, Series C-1 Convertible Preferred Stock, Series C-2 Convertible Preferred Stock, Series D Convertible Preferred Stock and Series E Convertible Preferred Stock held by the Stockholders. 

The terms “register,” “registered” and “registration” refer to a
registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement, or, as
the context may require, under the Exchange Act or applicable state securities laws. 
 “Registrable Securities”
means (i) shares of Common Stock issued upon the conversion of the Preferred Stock, (ii) for purposes of Sections 2.1, 2.2, 2.4, 2.6, 2.7, 2.8, 2.9, 2.14 and 2.15 only, shares of Common Stock held by the Common Stockholders as of the date
hereof, and (iii) any shares of Common Stock issued or issuable with respect to any of the foregoing upon any stock split, stock dividend, recapitalization, reorganization, merger, consolidation, sale of assets or similar event, excluding, in
any event, securities that (a) have been registered under the Securities Act pursuant to an effective registration statement filed thereunder and disposed of in accordance with such registration statement, (b) have been sold pursuant to
Rule 144, (c) are eligible for sale without volume restrictions pursuant to Rule 144 or (d) sold in a private transaction in which the transferor’s rights under Section 2 of this Agreement are not assigned. 

“Requisite Investors” means the holders of at least 60% of the then-outstanding Registrable Securities that were
issued upon conversion of the Series E Convertible Preferred Stock of the Company. 
 “Rule 144” means Rule 144 as
promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

“Securities Act” means the Securities Act of 1933, as amended, and any successor federal statute, and the rules and
regulations of the Commission thereunder, all as the same shall be in effect from time to time. 
 SECTION 2. TRANSFER OF REGISTRABLE SECURITIES;
REGISTRATION RIGHTS.  
 2.1 Restrictive Legend. Each certificate or uncertificated share representing Registrable
Securities shall, except as otherwise provided in this Section 2, be stamped or otherwise imprinted or notated, as applicable, with a legend substantially in the following form (in addition to any legend required under applicable state
securities laws): 
 “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR
ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933
AND ANY APPLICABLE STATE SECURITIES LAWS, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS THEREOF.” 
 Upon request
of a holder of such Registrable Securities, the Company shall remove the foregoing legend from the certificate or uncertificated shares or issue to such holder a new certificate or uncertificated shares therefor free of such legend if there is an
effective registration statement covering the securities represented by such certificate or uncertificated shares or, with such request, the Company shall have received either the opinion of counsel or no-action letter referred to in
Section 2.2 (unless such opinion of counsel or no-action letter is not required by Section 2.2), subject in each case to the continued effectiveness of such registration statement, opinion of counsel or no-action letter. 

2.2 Notice of Proposed Transfer. Prior to any proposed sale, pledge, hypothecation or other transfer of any Registrable Securities
(other than under the circumstances described in Section 2.3, 2.4 or 2.5), the holder thereof shall give written notice to the Company of its intention to effect such sale, pledge, hypothecation or other transfer. Each such notice shall
describe the manner of the proposed sale, pledge, hypothecation or other transfer and, if requested by the Company, shall be accompanied by either (i) an opinion of counsel reasonably satisfactory to the Company to the effect that the proposed
sale, pledge, hypothecation or other transfer may be effected without registration under the Securities Act or (ii) a “no-action” letter from the Commission to the effect that the distribution

  
 2 

 
of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto (it being understood that if such transfer, in
the reasonable opinion of the Company upon advice of its counsel, will be in accordance with Rule 144, the Company shall not require an opinion of counsel or no-action letter), whereupon the holder of such securities shall be entitled to transfer
such securities in accordance with the terms of its notice; provided, however, that no such opinion of counsel or no-action letter shall be required for a distribution to one or more partners of the transferor (in the case of a
transferor that is a partnership) or to a stockholder (in the case of a transferor that is a corporation) in each case in respect of the beneficial interest of such partner or stockholder. All certificates or uncertificated shares, as applicable,
for Registrable Securities transferred as provided above shall bear the appropriate restrictive legend set forth in Section 2.1, except that such certificate or uncertificated shares shall not bear such legend if (a) such transfer is in
accordance with the provisions of Rule 144 (or any other rule permitting public sale without registration under the Securities Act) or (b) the opinion of counsel or “no-action” letter referred to above is to the further effect that
the transferee and any subsequent transferee (other than an affiliate of the Company) would be entitled to transfer such securities in a public sale without registration under the Securities Act or that such legend is not required to establish
compliance with any provisions of the Securities Act. Notwithstanding any other provision hereof, the restrictions provided for in this Section 2.2 shall not apply to securities which are not required to bear the legend prescribed by
Section 2.1 in accordance with the provisions of that Section. 
 2.3 Required Registration. 

(a) At any time after the date that is 180 days following the date of the underwriting agreement for the Initial Offering,
holders of at least fifty percent (50%) of the total shares of Registrable Securities then outstanding may request that the Company register under the Securities Act all or any portion of the shares of Registrable Securities held by such
requesting holder or holders for sale in the manner specified in such notice, provided that the reasonably anticipated price to the public of such shares would be at least $7,500,000 (before deducting any Selling Expenses (as defined in
Section 2.7)). 
 (b) Following receipt of any notice under Section 2.3(a), the Company shall immediately notify
all holders of Registrable Securities from whom notice has not been received and such holders shall then be entitled within thirty (30) days after receipt of such notice from the Company to request the Company to include in the requested
registration all or any portion of their shares of Registrable Securities, subject to the limitations set forth in this Section 2.3(c). The Company shall use its best efforts to register under the Securities Act, for public sale in accordance
with the method of disposition specified in the notice from requesting holders described in paragraph (a) above, the number of shares of Registrable Securities specified in such notice (and in all notices received by the Company from other
holders within thirty (30) days after the receipt of such notice by such holders, subject to the limitations set forth in Section 2.3(c)). The Company shall be obligated to register Registrable Securities pursuant to this
Section 2.3 on two (2) occasions only; provided, however, that such obligation shall be deemed satisfied only when a registration statement covering all of the shares of Registrable Securities requested to be included in
such registration by the holders of Registrable Securities in accordance with the method of disposition specified by the requesting holders shall have become effective and, if such method of disposition is a firm commitment underwritten public
offering, all such shares shall have been sold pursuant thereto. Notwithstanding anything to the contrary contained herein, no request may be made under this Section 2.3 after the effective date of a registration statement filed by the Company
covering a firm commitment underwritten public offering and prior to ninety (90) days after the effective date of such registration statement. 

(c) If the holders requesting such registration intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.3 and the Company shall include such information in the written notice referred to in paragraph (b) above. The right of
any holder to registration pursuant to this Section 2.3 shall be conditioned upon such holder’s agreeing to participate in such underwriting and to permit inclusion of such holder’s Registrable Securities in the underwriting. If such
method of disposition is an underwritten public offering, the Company shall designate the managing underwriter of such offering, which underwriter shall be reasonably acceptable to the holders of at least a majority in interest of the shares of
Registrable Securities to be sold in such offering. A holder may elect to include in such underwriting all or a part of the Registrable Securities it holds, subject to the limitations required by the managing underwriter as provided for in
Section 2.3(d) below. 
 (d) A registration statement filed pursuant to this Section 2.3 may, subject to the
following provisions, include (i) shares of Common Stock for sale by the Company for its own account and (ii) shares of Common Stock held by persons who by virtue of agreements with the Company in compliance with the provisions of
Section 2.13 hereof are entitled to include such shares in such registration (the “Other Stockholders”), in each case for sale in accordance with the method of disposition specified by the requesting holders. If such
registration shall be underwritten, the Company and Other Stockholders proposing to distribute their shares through such underwriting shall enter into an underwriting agreement in customary form with the representative of the underwriter or

  
 3 

 
underwriters selected for such underwriting on terms no less favorable to the Company and such Other Stockholders than the terms afforded the holders of Registrable Securities. If and to the
extent that the managing underwriter determines that marketing factors require a limitation on the number of shares to be included in such registration, then the shares of Common Stock held by Other Stockholders (other than Registrable Securities)
and shares of Common Stock to be sold by the Company for its own account shall be excluded from such registration to the extent so required by such managing underwriter, and unless the holders of such shares and the Company have otherwise agreed in
writing, such exclusion shall be applied first to the shares held by the Other Stockholders to the extent required by the managing underwriter, then to the shares of Common Stock of the Company to be included for its own account to the extent
required by the managing underwriter. If the managing underwriter determines that marketing factors require a further limitation of the number of Registrable Securities to be registered under this Section 2.3, then Registrable Securities shall
be excluded in such manner that the securities to be sold shall be allocated among the selling holders pro rata based on their ownership of Registrable Securities; provided however that all Registrable Securities that were originally issued as
Common Stock shall be excluded before excluding any Registrable Securities that were originally issued as Preferred Stock. In any event all securities to be sold other than Registrable Securities will be excluded prior to any exclusion of
Registrable Securities. No Registrable Securities or any other security excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. If any holder of Registrable Securities or Other
Stockholder who has requested inclusion in such registration as provided above disapproves of the terms of the underwriting, such holder of securities may elect to withdraw therefrom by written notice to the Company and the managing underwriter. The
securities so withdrawn shall also be withdrawn from registration. Except for registration statements on Form S-4, S-8 or any comparable forms or successors thereto or another form not available for registering the Registrable Securities for sale to
the public, the Company will not file with the Commission any other registration statement with respect to its Common Stock, whether for its own account or that of other stockholders, from the date of receipt of a notice from requesting holders
pursuant to this Section 2.3 until one hundred eighty (180) days after the effective date of such registration, subject to the terms and conditions of this Agreement. 

(e) If at the time of any request to register Registrable Securities pursuant to this Section 2.3, the Company is engaged
in any activity which, in the good faith determination of the Board of Directors, would be adversely affected by the requested registration to the material detriment of the Company, then the Company may, at its option, direct that such request be
delayed for a period not to exceed ninety (90) days from the date of a request for registration, such right to delay a request to be exercised by the Company not more than once in any one (1)-year period.

 2.4 Incidental Registration. If the Company at any time proposes to register any of its securities under the Securities Act for
sale to the public, whether for its own account or for the account of other security holders or both (except with respect to registration statements on Forms S-4, S-8 or any comparable forms or successors thereto or another form not available for
registering the Registrable Securities for sale to the public), each such time it will promptly give written notice to all holders of the Registrable Securities of its intention so to do. Upon the written request of any such holder received by the
Company within twenty (20) days after the giving of any such notice by the Company to register any or all of its Registrable Securities, the Company will use its best efforts to cause the Registrable Securities as to which registration shall have
been so requested to be included in the securities to be covered by the registration statement proposed to be filed by the Company, all to the extent required to permit the sale or other disposition by the holder (in accordance with its written
request) of such Registrable Securities so registered. If the registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the holders of Registrable Securities as a part
of the written notice given pursuant to this Section 2.4. In such event the right of any holder of Registrable Securities to registration pursuant to this Section 2.4 shall be conditioned upon such holder’s participation in such underwriting to
the extent provided herein. All holders of Registrable Securities proposing to distribute their securities through such underwriting shall (together with the Company and the Other Stockholders distributing their securities through such underwriting)
enter into an underwriting agreement in customary form with the underwriter or underwriters selected for underwriting by the Company. Notwithstanding any other provision of this Section 2.4, if the underwriter determines that marketing factors
require a limitation on the number of shares to be underwritten, such limitation will be imposed pro rata with respect to all securities whose holders have a contractual, incidental (“piggyback”) right to include such securities in the
registration statement and as to which inclusion has been requested pursuant to such right; provided, however, that the number of Registrable Securities shall not be reduced below thirty percent (30%) of the number of Registrable
Securities requested to be included in such underwriting; and provided further that the number of Registrable Securities underlying Preferred Stock shall not be reduced below twenty-five percent (25%) of the number of securities
included in such underwriting. Notwithstanding the foregoing provisions, the Company may withdraw any registration statement referred to in this Section 2.4 for any reason without thereby incurring any liability to the holders of Registrable
Securities. If any holder of Registrable Securities disapproves of the terms of any such underwriting, it may elect to withdraw therefrom by written notice to the Company and the underwriter. Any Registrable Securities or other securities excluded
or withdrawn from such underwriting shall be withdrawn from such registration. 

  
 4 

 2.5 Registration on Form S-3. 

(a) In addition to the rights provided in Sections 2.3 and 2.4, if at any time (i) one or more holders of Registrable
Securities constituting at least fifty percent (50%) of the total shares of Registrable Securities then outstanding requests that the Company file a registration statement on Form S-3 or any comparable or successor form thereto for a public
offering of all or any portion of the shares of Registrable Securities held by such requesting holder or holders, the reasonably anticipated aggregate price to the public of which would be at least $5,000,000 (before deducting any Selling Expenses),
and (ii) the Company is a registrant entitled to use Form S-3 or any comparable or successor form thereto to register such shares, then the Company shall use its best efforts to register under the Securities Act on Form S-3 or any comparable or
successor form thereto, for public sale in accordance with the method of disposition specified in such notice, the number of shares of Registrable Securities specified in such notice. Whenever the Company is required by this Section 2.5 to use
its best efforts to effect the registration of Registrable Securities, each of the procedures and requirements of Section 2.3, including, but not limited to, the cut-back provisions and the requirement that the Company notify all holders of
Registrable Securities from whom notice has not been received and provide them with the opportunity to participate in the offering, shall apply to such registration; provided, however, that the number of registrations on Form S-3 which
may be requested and obtained under this Section 2.5 during any twelve (12)-month period shall not exceed two (2). 

(b) The Company shall use its commercially reasonable efforts to qualify for registration on Form S-3 or any comparable or
successor form or forms; and to that end the Company shall use its commercially reasonable efforts to register (whether or not required by law to do so) the Common Stock under the Exchange Act in accordance with the provisions of the Exchange Act
following the effective date of the first registration of any securities of the Company on Form S-1 or any comparable or successor form. 

(c) If at the time of any request to register Registrable Securities pursuant to this Section 2.5, the Company is engaged
in any activity which, in the good faith determination of the Board of Directors, would be adversely affected by the requested registration to the material detriment of the Company, then the Company may at its option direct that such request be
delayed for a period not to exceed ninety (90) days from the date of a request for registration, such right to delay a request to be exercised by the Company not more than once in any one (1)-year period.

 2.6 Registration Procedures. If and whenever the Company is required by the provisions of Section 2.3, 2.4 or 2.5 to use its
best efforts to effect the registration of any Registrable Securities under the Securities Act, the Company will, as expeditiously as possible: 

(a) prepare and file with the Commission a registration statement (which, in the case of an underwritten public offering
pursuant to Section 2.3, shall be on Form S-1 or other form of general applicability satisfactory to the managing underwriter selected as therein provided) with respect to such securities including executing an undertaking to file
post-effective amendments and use its best efforts to cause such registration statement to become and remain effective for the period of the distribution contemplated thereby; 

(b) prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus
used in connection therewith as may be necessary to keep such registration statement effective for the period specified herein and comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered
by such registration statement in accordance with the sellers’ intended method of disposition set forth in such registration statement for such period; 

(c) furnish to each seller of Registrable Securities and to each underwriter such number of copies of the registration
statement and each such amendment and supplement thereto (in each case including all exhibits) and the prospectus included therein (including each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale
or other disposition of the Registrable Securities covered by such registration statement; 
 (d) use its best efforts to
register or qualify the Registrable Securities covered by such registration statement under the securities or “blue sky” laws of such jurisdictions as the sellers of Registrable Securities or, in the case of an underwritten public
offering, the managing underwriter reasonably shall request; 
 (e) use its best efforts to list the Registrable Securities
covered by such registration statement with any securities exchange or quotation system on which the Common Stock of the Company is then listed; 

  
 5 

 (f) comply with all applicable rules and regulations under the Securities Act and
Exchange Act; 
 (g) immediately notify each seller of Registrable Securities and each underwriter under such registration
statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event of which the Company has knowledge as a result of which the prospectus contained in such registration
statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, and
promptly prepare and furnish to such seller a reasonable number of copies of a prospectus supplement or amendment so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 

(h) if the offering is underwritten and at the request of any seller of Registrable Securities, furnish on the date that
Registrable Securities are delivered to the underwriters for sale pursuant to such registration: (i) an opinion of counsel representing the Company for the purposes of such registration, dated such date, addressed to the underwriters to such
effects as reasonably may be requested by counsel for the underwriters, and executed counterparts of such opinion addressed to the sellers of Registrable Securities to the same effects as requested by counsel for the underwriters, and (ii) a
letter, dated such date, from the independent public accountants retained by the Company, addressed to the underwriters stating that they are independent public accountants within the meaning of the Securities Act and that, in the opinion of such
accountants, the financial statements of the Company included in the registration statement or the prospectus, or any amendment or supplement thereof, comply as to form in all material respects with the applicable accounting requirements of the
Securities Act, and such letter shall additionally cover such other financial matters with respect to such registration as such underwriters reasonably may request; 

(i) make available for inspection by each seller of Registrable Securities, any underwriter participating in any distribution
pursuant to such registration statement and any attorney, accountant or other agent retained by such seller or underwriter, reasonable access to all financial and other records, pertinent corporate documents and properties of the Company, as such
parties may reasonably request, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such registration
statement; 
 (j) cooperate with the selling holders of Registrable Securities and the managing underwriter, if any, to
facilitate the timely preparation and delivery of certificates or uncertificated shares representing Registrable Securities to be sold, such certificates or uncertificated shares to be in such denominations and registered in such names as such
holders or the managing underwriter may request at least two (2) business days prior to any sale of Registrable Securities; and 

(k) permit any holder of Registrable Securities which holder, in the sole and exclusive judgment, exercised in good faith, of
such holder, might be deemed to be a controlling person of the Company, to participate in good faith in the preparation of such registration or comparable statement and to require the insertion therein of material, furnished to the Company in
writing, which in the reasonable judgment of such holder and its counsel should be included. 
 For purposes of this
Agreement, the period of distribution of Registrable Securities in a firm commitment underwritten public offering shall be deemed to extend until each underwriter has completed the distribution of all securities purchased by it, and the period of
distribution of Registrable Securities in any other registration shall be deemed to extend until the earlier of the sale of all Registrable Securities covered thereby or one hundred eighty (180) days after the effective date thereof,
provided, however, in the case of any registration of Registrable Securities on Form S-3 or a comparable or successor form which are intended to be offered on a continuous or delayed basis, such
one hundred eighty (180)-day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule
under the Securities Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Securities Act governing the obligation to file a post-effective amendment, permit, in lieu of filing a
post-effective amendment which (y) includes any prospectus required by Section 10(a)(3) of the Securities Act or (z) reflects facts or events representing a material or fundamental change in the information set forth in the
registration statement, the incorporation by reference of information required to be included in clauses (y) and (z) above contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration
statement. 
 In connection with each registration hereunder, the sellers of Registrable Securities will furnish to the
Company in writing such information requested by the Company and the managing underwriter, if any, with respect to themselves and the proposed distribution by them as shall be reasonably necessary in order to assure compliance with Federal and
applicable state securities laws. Any holder of 

  
 6 

 
Registrable Securities may withdraw all or part of its Registrable Securities from a registration pursuant to Section 2.3, 2.4 or 2.5 at any time prior to the effective date of such
registration. 
 2.7 Expenses. 

(a) All expenses incurred by the Company in complying with Sections 2.3, 2.4 and 2.5, including, without limitation, all
registration and filing fees, printing expenses, fees and disbursements of counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred in connection with complying with state securities or
“blue sky” laws, fees of the Financial Industry Regulatory Authority (FINRA), transfer taxes, fees of transfer agents and registrars, costs of any insurance which might be obtained by the Company with respect to the offering by the
Company, and reasonable fees and disbursements of one counsel selected by at least a majority in interest of the sellers of Registrable Securities (which fees and disbursements of counsel shall not exceed $25,000 per required registration or S-3
registration and shall not exceed an aggregate of $50,000 for all registrations effected during any twelve (12)-month period), but excluding any Selling Expenses, are called “Registration
Expenses”. All underwriting discounts and selling commissions applicable to the sale of Registrable Securities are called “Selling Expenses.” 

(b) The Company will pay all Registration Expenses incurred in connection with any registration pursuant to Section 2.3,
2.4 or 2.5; provided, however, if any registration requested pursuant to Section 2.3 or 2.5 is withdrawn at the request of the holders initiating such registration, such holders may elect to (i) have the Company pay the
Registration Expenses for such withdrawn registration but such withdrawn registration shall count as a completed registration toward the Company’s obligation pursuant to Section 2.3(b) or 2.5(a), as the case may be, or (ii) pay the
Registration Expenses for such withdrawn registration but such withdrawn registration shall not count as a completed registration toward the Company’s obligation under Section 2.3(b) or 2.5(a), as the case may be; provided
further, however, that if a registration is withdrawn after the holders of Registrable Securities initiating such registration have learned of a material adverse change in the financial condition or prospects of the Company or have
learned of other material adverse information relating to the Company, in either case not known to such holders at the time of their request for such registration, then all Registration Expenses related to such withdrawn registration shall be borne
by the Company and such withdrawn registration shall not be counted as a completed registration under Section 2.3(b) or 2.5(a), as the case may be. All Selling Expenses in connection with each registration statement under Section 2.3, 2.4
or 2.5 shall be borne by the participating sellers in proportion to the number of shares sold by each, or by such participating sellers other than the Company as they may agree. 

2.8 Indemnification and Contribution.  

(a) In connection with a registration of any of the Registrable Securities under the Securities Act pursuant to Section 2.3,
2.4 or 2.5, the Company will indemnify and hold harmless each seller of Registrable Securities, its officers, directors and partners, each underwriter of such Registrable Securities thereunder and each other person, if any, who controls such holder
or underwriter within the meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to which such holder, officer, director, partner, underwriter or controlling person may become subject under the
Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in any prospectus,
offering circular or other document incident to such registration (including any related notification, registration statement under which such Registrable Securities were registered under the Securities Act pursuant to Section 2.3, 2.4 or 2.5, any
preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof), (ii) any blue sky application or other document executed by the Company specifically for that purpose or based upon written information furnished
by the Company filed in any state or other jurisdiction in order to qualify any or all of the Registrable Securities under the securities laws thereof (any such application, document or information herein called a “Blue Sky
Application”), (iii) any omission or alleged omission to state in any such registration statement, prospectus, amendment or supplement or in any Blue Sky Application executed or filed by the Company, a material fact required to be
stated therein or necessary to make the statements therein not misleading, (iv) any violation by the Company or its agents of the Securities Act or any rule or regulation promulgated under the Securities Act applicable to the Company or its agents
and relating to action or inaction required of the Company in connection with such registration, or (v) any failure to register or qualify the Registrable Securities in any state where the Company or its agents has affirmatively undertaken or agreed
in writing that the Company (the undertaking of any underwriter chosen by the Company being attributed to the Company) will undertake such registration or qualification (provided that in such instance the Company shall not be so liable if it has
used its best efforts to so register or qualify the Registrable Securities) and will reimburse each such seller, and such officer, director and partner, each such underwriter and each such controlling person for any legal or other expenses
reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action, promptly after being so incurred, provided, however, that the Company will not be liable in any such case for
any amounts paid in settlement of any losses, claims, damages or liabilities if such settlement is effected without the consent of the Company, which consent shall not be 

  
 7 

 
unreasonably withheld, and, provided further, however, that the Company will not be liable in any such case if and to the extent that any such loss, claim, damage or
liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with written information furnished by any such holder, any such underwriter or any such controlling person
in writing specifically for use in such registration statement or prospectus. 
 (b) In connection with a registration of
any of the Registrable Securities under the Securities Act pursuant to Section 2.3, 2.4 or 2.5, each seller of such Registrable Securities thereunder, severally and not jointly, will indemnify and hold harmless the Company, each person, if any,
who controls the Company within the meaning of the Securities Act, each officer of the Company, each director of the Company, each other seller of Registrable Securities, each underwriter and each person who controls any underwriter within the
meaning of the Securities Act, against all losses, claims, damages or liabilities, joint or several, to which the Company or such officer, director, other seller, underwriter or controlling person may become subject under the Securities Act or
otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in any prospectus, offering circular or
other document incident to such registration (including any related notification, registration statement under which such Registrable Securities were registered under the Securities Act pursuant to Section 2.3, 2.4 or 2.5, any preliminary
prospectus or final prospectus contained therein, or any amendment or supplement thereof), or any Blue Sky Application or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading, and will reimburse the Company and each such officer, director, other seller, underwriter and controlling person for any legal or other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, damage, liability or action, promptly after being so incurred, provided, however, that such seller will be liable hereunder in any such case if and only to the extent that any such
loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information pertaining to such seller, as such, furnished in
writing to the Company by such seller specifically for use in such registration statement or prospectus and, provided that, in no event shall such seller be liable for any amounts paid in settlement of any losses, claims, damages or liabilities if
such settlement is effected without the consent of such seller, which consent shall not be unreasonably withheld, and provided further, however, that the liability of each seller hereunder shall be limited to the proportion of
any such loss, claim, damage, liability or expense which is equal to the proportion that the public offering price of the securities sold by such seller under such registration statement bears to the total public offering price of all securities
sold thereunder, but not in any event to exceed the proceeds received by such seller from the sale of Registrable Securities covered by such registration statement. Not in limitation of the foregoing, it is understood and agreed that the
indemnification obligations of any seller hereunder pursuant to any underwriting agreement entered into in connection herewith shall be limited to the obligations contained in this subparagraph (b). 

(c) Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified
party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party in writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which
it may have to such indemnified party unless and to the extent the indemnifying party is prejudiced by such omission. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel satisfactory to such indemnified party and, after notice from the
indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not be liable to such indemnified party under this Section 2.8 for any legal expenses subsequently
incurred by such indemnified party in connection with the defense thereof, provided, however, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have
reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party or that the interests of the indemnified party reasonably may be deemed to conflict with
the interests of the indemnifying party, the indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to select one separate counsel and to assume such legal
defenses and otherwise to participate in the defense of such action, with the expenses and fees of such separate counsel and other reasonable expenses related to such participation to be reimbursed by the indemnifying party as incurred. No
indemnifying party, in the defense of any such claim or action, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or action. Each indemnified party shall furnish such information regarding itself or the claim in question as an indemnifying
party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. 

(d) In order to provide for just and equitable contribution to joint liability under the Securities Act in any case in which
either (i) any holder of Registrable Securities exercising rights under this Agreement, or any controlling person of any such holder, 

  
 8 

 
makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any such selling holder or any such controlling person in circumstances for which indemnification is provided under this Section 2.8; then, and in each such case,
the Company and such holder will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of the indemnifying
party on the one hand and the indemnified party on the other hand in connection with the actions or omissions which resulted in such losses, claims, damages or liabilities (or actions or proceedings in respect thereof), as well as any other
equitable considerations, it being understood that the relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission, provided, however, that, in any such case, (A) no such holder of Registrable Securities will be required to contribute any amount in excess of the proceeds received from the sale of all such
Registrable Securities offered by it pursuant to such registration statement; and (B) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution
from any person or entity who was not guilty of such fraudulent misrepresentation. 
 (e) The indemnities and obligations
provided in this Section 2.8 shall survive the transfer of any Registrable Securities by such holder effected in accordance with this Agreement or the termination of any registration rights granted hereunder. 

2.9 Changes in Common Stock. If, and as often as, there is any change in the Common Stock by way of a stock split, stock dividend,
combination or reclassification, or through a merger, consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof so that the rights and privileges granted hereby shall
continue with respect to the Common Stock as so changed. 
 2.10 Rule 144 and 144A Reporting. With a view to making available the
benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Registrable Securities to the public without registration, at all times after any registration statement covering a public offering of
securities of the Company under the Securities Act shall have become effective, the Company agrees to: 
 (a) use its best
efforts to comply with all of the reporting requirements of the Exchange Act and shall use its best efforts to comply with all other public information reporting requirements of the Commission as a condition to the availability of an exemption from
the Securities Act for the sale of any of the Registrable Securities by any holder of Registrable Securities (including any such exemption pursuant to Rule 144 or Rule 144A thereof); 

(b) cooperate with each holder of Registrable Securities in supplying such information as may be necessary for such holder of
Registrable Securities to complete and file any information reporting forms presently or hereafter required by the Commission as a condition to the availability of an exemption from the Securities Act (under Rule 144 or Rule 144A thereunder or
otherwise) for the sale of any of the Registrable Securities by any holder of Registrable Securities; and 
 (c) furnish to
each holder of Registrable Securities forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of Rule 144 or Rule 144A (or any successor rule), and such information as such holder may reasonably
request in availing itself of any rule or regulation of the Commission allowing such holder to sell any Registrable Securities without registration. 

2.11 [Reserved].  

2.12 “Market Stand-Off” Agreement. Each of the Stockholders hereby agrees, severally and not jointly, if requested by the
Company and an underwriter of securities of the Company, not to directly or indirectly sell, offer to sell, contract to sell (including, without limitation, any short sale or other similar hedging transaction), grant any option to purchase or
otherwise transfer or dispose of (other than to transferees who agree to be similarly bound) any Common Stock or securities of the Company convertible into capital stock of the Company held by such Stockholder (but excluding any shares acquired in
or following the Initial Offering) during the one hundred and eighty (180) day period following the effective date of the registration statement for the Initial Offering and to enter into a written agreement with such underwriter to that effect,
provided that: 

  
 9 

 (a) all executive officers and directors of the Company and all holders of five
percent (5%) or greater of the outstanding capital stock of the Company enter into similar agreements; and 
 (b) the
Company uses its reasonable efforts to cause the managing underwriter to agree to permit periodic early releases of the capital stock of the Company held by the Stockholders that is subject to the foregoing restrictions and, in the event that the
managing underwriter permits such early releases, the capital stock of the Company held by all Stockholders is released on a pro rata basis (providing such managing underwriter will not be required to effect any pro rata release unless and until
such managing underwriter has first released more than three percent (3%) of the Company’s total outstanding shares from such lock-up). 

The Company may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing
restriction until the end of said period. Each of the Stockholders agrees to sign such agreements or documents reasonably requested by the Company and/or the managing underwriters relating to and consistent with the provisions of this
Section 2.12. 
 2.13 Limitation on Subsequent Registration Rights. The Company shall not grant to any Person any registration
rights without the consent of the Requisite Investors, other than registration rights that are subordinate to or on parity with the registration rights contained herein. 

2.14 Assignment of Registration Rights. Notwithstanding any provision of this Agreement to the contrary, the rights to cause the
Company to register Registrable Securities pursuant to this Section 2 may be assigned (but only with all related obligations) by a holder of Registrable Securities to a transferee or assignee of such securities who, after such assignment or
transfer, holds at least 200,000 shares of such class or series of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations and other recapitalizations effected following the closing of the Initial
Offering), or such lesser number of shares if such number represents all shares of Registrable Securities held by the holder transferring such Registrable Securities; provided that the Company is, within a reasonable time after such transfer,
furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; and provided further, that the transferee or assignee shall
acknowledge in writing that the transferred or assigned Registrable Securities shall remain subject to this Agreement. Notwithstanding the foregoing, a holder of Registrable Securities may assign its rights under this Section 2 in accordance
with the preceding sentence to any Affiliate, member, principal, director, partner or stockholder of such holder (including spouses and ancestors, lineal descendants and siblings of such members, principals, directors, partners or stockholders who
acquire Registrable Securities by gift, will or intestate succession) without regard to the minimum share requirement set forth above. 

2.15 Termination of Registration Rights. The Company’s obligations under Sections 2.3, 2.4 and 2.5 to register the Registrable
Securities shall terminate on the second (2nd) anniversary of the closing of the Initial Offering. In addition, a Stockholder’s registration rights under this Section 2 shall expire
if all Registrable Securities held by and issuable to such Stockholder may be sold under Rule 144 during any ninety (90)-day period. 

SECTION 3. CERTAIN COVENANTS 
 3.1
Qualified Small Business. The Company shall submit to its stockholders and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Internal Revenue Code (the “Code”) and
the regulations promulgated thereunder. In addition, within ten (10) days after an Investor’s written request therefor, the Company shall furnish such Investor with a written statement informing such Investor whether such Investor’s
Registrable Securities constitute “Qualified Small Business Stock” (as defined in Section 1202(c) of the Internal Revenue Code of 1986, as amended). 

SECTION 4. MISCELLANEOUS.  

4.1 Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the
receiving party’s address set forth below or to such other address as a party may designate by notice hereunder, and shall be either (i) delivered by hand, (ii) made by electronic mail or facsimile transmission, (iii) sent by
overnight courier or (iv) sent by registered or certified mail, return receipt requested, postage prepaid. 
 If to the Company: 

HTG Molecular Diagnostics, Inc. 

3430 E. Global Loop 

  
 10 

 
					
	 Tucson, AZ 85706
	 	
	 Attn: President
	 	
	 Phone:
	 	(877) 289-2615	 	
	 Fax:
	 	(520) 547-2837	 	

 With a copy to: 

 

					
	Cooley LLP	  	
	4401 Eastgate Mall	  	
	San Diego, CA 92121	  	
	Attn: Steve M. Przesmicki, Esq.	  	
	Phone:	 	(858) 550-6070	  	
	Fax:	 	(858) 550-6420	  	

 If to the Common Stockholders: To the addresses set forth on Exhibit A-1 hereto. 

If to the Investors: To the addresses set forth on Exhibit A-2 hereto. 

All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i) if by hand, at the time
of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if made by electronic mail or facsimile transmission, at the time that receipt thereof has been acknowledged by electronic confirmation or
otherwise, if sent during normal business hours of the recipient, and if not send during normal business hours of the recipient, then on the next business day, (iii) if sent by overnight courier, on the next business day (or if sent overseas,
on the second (2nd) business day) following the day such notice is delivered to the courier service or (iv) if sent by registered or certified mail, on the fifth (5th) business day (or if sent overseas, on the tenth
(10th) business day) following the day such mailing is made. 
 4.2 Entire Agreement. This Agreement embodies the entire
agreement and understanding between the parties hereto with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings relating to the subject matter hereof, including, without limitation, the Prior
Agreement. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. 

4.3 Waivers and Amendment. Except as otherwise expressly provided, any term of this Agreement may be amended and the observance of any
term of this Agreement may be waived (either generally or in any particular instance), only with the written consent of the Company and the Requisite Investors. Notwithstanding the foregoing, (A) (i) any amendment or waiver of the
definition of Registrable Securities or of Section 2.4 that would have the effect of eliminating the right of Common Stockholders to include Registrable Securities pursuant to Section 2.4 in a registration, (ii) any amendment or
waiver of the last sentence of Section 1.1 or of Sections 2.1, 2.2, 2.8 or 2.12, (iii) any amendment or waiver of any other provision of this Agreement that would impose additional obligations on the Common Stockholders without imposing
similar obligations on the Investors or would adversely affect the rights or obligations of Common Stockholders without having a similar adverse effect on the rights of the Investors, and (iv) any amendment or waiver of the foregoing clauses
(i), (ii), (iii) and this clause (iv), shall also require the written consent of Common Stockholders holding at least a majority of the then outstanding Registrable Securities held by all Common Stockholders, and (B) the right of any
Stockholder may be waived to the extent that such waiver applies solely to such Stockholder’s rights by such Stockholder. Any waiver or amendment effected in accordance with the terms hereof shall be binding upon all Stockholders and the
Company. Upon the effectuation of each such waiver or amendment, the Company shall promptly give written notice thereof to the Stockholders who have not previously consented thereto in writing. 

4.4 Assignment. The rights and obligations under this Agreement may not be assigned by the Company or any Common Stockholder without
the prior written consent of the Requisite Investors, unless pursuant to a transfer of Registrable Securities specifically permitted by the terms hereof. 

4.5 Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties
hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity
shall be regarded as a third-party beneficiary of this Agreement, except indemnitees pursuant to Article 2 hereof. 

  
 11 

 4.6 Governing Law. This Agreement shall be construed and enforced in accordance with and
governed by the State of Delaware, without giving effect to the conflicts of law principles thereof. 
 4.7 Severability. In the
event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in this Agreement shall be unenforceable in any respect, then such provision shall be deemed limited to the extent that such court
deems it enforceable, and as so limited shall remain in full force and effect. In the event that such court shall deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall nevertheless remain
in full force and effect. 
 4.8 Interpretation. The parties hereto acknowledge and agree that: (i) each party and its counsel
reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the
interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to all parties hereto and not in favor of or against any party, regardless of which party was generally responsible for the
preparation of this Agreement. 
 4.9 Headings and Captions. The headings and captions of the various subdivisions of this Agreement
are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof. All pronouns used in this Agreement shall be deemed to include masculine, feminine and neuter forms, the
singular number includes the plural and the plural number includes the singular. 
 4.10 Enforcement. Each of the parties hereto
acknowledges and agrees that the rights acquired by each party hereunder are unique and that irreparable damage would occur in the event that any of the provisions of this Agreement to be performed by the other parties were not performed in
accordance with their specific terms or were otherwise breached. Accordingly, in addition to any other remedy to which the parties hereto are entitled at law or in equity, each party hereto shall be entitled to an injunction or injunctions to
prevent breaches of this Agreement by any other party and to enforce specifically the terms and provisions hereof in any federal or state court to which the parties have agreed hereunder to submit to jurisdiction. 

4.11 No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under
this Agreement, and no course of dealing among the parties hereto, shall operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any
abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a
party hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any
other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand. 

4.10 Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of signatures by facsimile or PDF will be as effective as the delivery of original signatures. 

4.11 Aggregation of Stock. All shares of Registrable Securities held by any Stockholder and its Affiliates shall be aggregated for
determining the availability of any rights under this Agreement. 
 4.12 Confidentiality. Each Investor agrees to hold all
confidential information received pursuant to this Agreement in confidence, and not to use or disclose any of such information to any third party, except to the extent that such information may be made publicly available by the Company and other
than to monitor and maintain its investment in the Company; provided, however, that any Investor may, in the ordinary course of business, provide the financial results of the Company to its stockholders, partners or members in the same manner such
information is provided by such Investor with respect to its portfolio companies. 
 4.13 Section References. References herein to
“Articles” and “Sections” herein shall be to Articles and Sections of this Agreement. 
 [REMAINDER
OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 12 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	COMPANY:
	
	HTG MOLECULAR DIAGNOSTICS, INC.
		
	Signature:	 	 /s/ Timothy Johnson

	Print Name:	 	Timothy Johnson
	Title:	 	President and Chief Executive
Officer

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	INVESTOR:
	
	S.R. ONE, LIMITED
		
	By:	 	 /s/ Simeon J. George

	Name: Simeon J. George
	Title: Vice President and Partner

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	 INVESTOR:

	
	 NOVO A/S

		
	 By:
	 	 /s/ Jack B. Nielsen

	 Name: Jack B. Nielsen

	 Title: Partner

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	 INVESTOR:

	
	 Fletcher Spaght Ventures II, L.P.

	 By: Fletcher Spaght Associates II, L.P., its General Partner

	 By: FSA II, LLC, its General Partner

		
	 By:
	 	 /s/ R. John Fletcher

		
	 Name:
	 	 R. John Fletcher

	
	 Title: Managing Member

	
	 FSV II, L.P.

	 By: Fletcher Spaght Associates II, L.P., its General Partner

	 By: FSA II, LLC, its General Partner

		
	 By:
	 	 /s/ R. John Fletcher

		
	 Name:
	 	 R. John Fletcher

	
	 Title: Managing Member

	
	 FSV II-B, L.P.

	 By: Fletcher Spaght Associates II-B, LLC, its General Partner

	 By: FSA II, LLC, its Manager

		
	 By:
	 	 /s/ R. John Fletcher

		
	 Name:
	 	 R. John Fletcher

	
	 Title: Managing Member

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	 INVESTOR:

	
	 MERCK CAPITAL VENTURES, LLC

		
	 By:
	 	 /s/ Lawrence D. Senour

	 Name: Lawrence D. Senour

	 Title: Executive Director, Corporate Development

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	 INVESTOR:

	
	 SOLSTICE CAPITAL II, L.P.

	 By: Solstice Capital LLC, its general partner

		
	 By:
	 	 /s/ Harry A. George

	 Name: Harry A. George

	 Title: Managing Member

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

	
	 INVESTOR:

	
	 /s/ Jim Weersing

	 JIM WEERSING, TRUSTEE OF THE
WEERSING

	 FAMILY TRUST

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

					
		 	COMMON STOCKHOLDERS:	  	
			
		 	 /s/ Bruce Seligman
	  	
		 	 BRUCE SELIGMANN, TRUSTEE OF THE
SELIGMANN-JUNGHANS
 FAMILY TRUST U/A/D JULY 9, 1999

			
		 	 /s/ Bruce Seligman
	  	
		 	BRUCE SELIGMANN	  	

 EXHIBIT A-1 

COMMON STOCKHOLDERS 
  

					
	 NAME AND ADDRESS OF

 
 STOCKHOLDER
	  	
COMMON STOCK
  
	  	
OPTIONS
  

	 Seligmann-Junghans
Family
 Trust U/A/D July 9, 1999
 Address on file with
Company
  
	  	5,105,714	  	 
	 Ralph R. Martel

Address on file with Company
  
	  	140,000	  	 
	 Constance A.
Junghans
 Address on file with Company
  
	  	498,130	  	 
	 Timothy B.
Johnson
 Address on file with Company
  
	  	 	  	11,863,118
	 Bruce Seligmann

Address on file with Company
  
	  	657,000	  	1,859,510
	 Pete Clemens

Address on file with Company
  
	  	138,750	  	 
	 Shaun McMeans

Address on file with Company
  
	  	 	  	2,499,162
	 John Lubniewski

Address on file with Company
  
	  	 	  	3,476,196
	 Stephen Hagan

Address on file with Company
  
	  	 	  	1,915,969
	 Debra Gordon

Address on file with Company
  
	  	 	  	893,840
	 Donald Ball

Address on file with Company
  
	  	 	  	746,710
	 Vijay Modur

Address on file with Company
  
	  	 	  	2,599,162

 EXHIBIT A-2 

INVESTORS 
  

													
	
NAME AND ADDRESS OF
  

STOCKHOLDER
	 	   SERIES  

 
 A
	 	  SERIES B  	 	   SERIES  

 
 C-1
	 	   SERIES  

 
 C-2
	 	  SERIES D  	 	  SERIES E  
	 S.R. One,
Limited
 Address on file with Company

 
	 	 	 	 	 	 	 	 	 	36,546,366	 	15,227,653
	 NOVO
A/S
 Address on file with Company
  
	 	 	 	 	 	 	 	 	 	50,251,254	 	15,227,653
	 Fletcher Spaght Ventures II, L.P. c/o Fletcher

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	16,801,503	 	3,862,416
	 FSV II,
L.P.
 c/o Fletcher Spaght, Inc./ Fletcher Spaght

Ventures

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	1,692,017	 	388,969
	 FSV II-B,
L.P.
 c/o Fletcher Spaght, Inc./ Fletcher Spaght

Ventures

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	8,002,596	 	1,839,677
	 MERCK
CAPITAL VENTURES, LLC
 Address on file with Company

 
 WITH A COPY TO:

 
 Edwards Angell Palmer & Dodge

Address on file with Company
  
	 	 	 	 	 	8,670,520	 	9,601,924	 	20,658,958	 	7,613,826
	  

Solstice Capital II, L.P.

Address on file with Company
  
	 	574,212	 	4,183,874	 	1,547,390	 	4,157,017	 	1,888,295	 	 
	 Valley
Ventures III, L.P.
 Address on file with Company

 
	 	459,369	 	3,616,906	 	516,010	 	992,890	 	586,281	 	 
	 Valley
Ventures III Annex, L.P.
 Address on file with Company

 
	 	 	 	 	 	1,083,815	 	2,978,666	 	1,758,843	 	 

													
	 NAME AND ADDRESS OF

 
 STOCKHOLDER
	 	
  SERIES  
  

A
	 	  SERIES B  	 	
  SERIES  
  

C-1
	 	
  SERIES  
  

C-2
	 	  SERIES D  	 	  SERIES E  
	 Village Ventures Partners Fund, L.P.

Address on file with Company
  

With a copy to:
  

Village Ventures, Inc.
 Address on file with Company

 
	 	106,227	 	768,556	 	286,254	 	 	 	 	 	 
	 Village Ventures Partners Fund A, L.P.

c/o Village Ventures, Inc.
 Address on file with Company

 
 With a copy to:

 
 Village Ventures, Inc.

Address on file with Company
  
	 	8,041	 	58,199	 	21,675	 	 	 	 	 	 
	 VVN, LLC

c/o Village Ventures, Inc.
 Address on file with Company

 
 With a copy to:

 
 Village Ventures, Inc.

Address on file with Company
  
	 	574	 	4,154	 	1,547	 	 	 	 	 	 
	 GC&H INVESTMENTS, LLC

Address on file with Company
  
	 	 	 	 	 	72,254	 	 	 	90,394	 	 
	 ETP/FBR Venture Capital II, LLC

Address on file with Company
  
	 	 	 	691,227	 	308,527	 	 	 	 	 	 
	 PALICE INVESTMENTS, LLC

Address on file with Company
  
	 	 	 	 	 	380,829	 	 	 	238,220	 	 
	 415 Golf View LLC

c/o Granger L. Vinall
 Address on file with Company

 
	 	 	 	 	 	37,085	 	 	 	 	 	 
	 Miramar Ventures, LLC

c/o David C. Smallhouse
 Address on file with Company

 
	 	 	 	164,577	 	314,915	 	 	 	 	 	 
	 Steven P. Sim and Marilyn B. Einstein

Address on file with Company
  
	 	 	 	65,138	 	148,341	 	 	 	 	 	 
	 Edward B. Berger and Christina McComb-

Berger Family Trust dated December 6, 2002
 c/o Edward B.
Berger and Christina McComb-Berger Family Trust
 Address on file with Company

 
	 	 	 	82,165	 	74,170	 	 	 	 	 	 

													
	
NAME AND ADDRESS OF
  

STOCKHOLDER
	 	   SERIES  

 
 A
	 	  SERIES B  	 	   SERIES  

 
 C-1
	 	   SERIES  

 
 C-2
	 	  SERIES D  	 	  SERIES E  
	 Curtis Gunn

Address on file with Company
  
	 	 	 	32,611	 	451,923	 	 	 	 	 	 
	 Weintraub Family Trust W/A dtd 03/13/80

Ronald H. Weintraub &
Diane B. Weintraub,

Trustees
 Address on file with Company

 
	 	 	 	65,831	 	74,154	 	 	 	 	 	 
	 Pierre Sice & Genevieve Sice, Community

Property
 Address on file with Company

 
	 	 	 	101,205	 	 	 	 	 	95,164	 	 
	 Pierre Sice

Address on file with Company
  
	 	 	 	 	 	73,917	 	 	 	 	 	 
	 Ralph R. Martel

Address on file with Company
  
	 	 	 	 	 	44,212	 	 	 	 	 	 
	 Lawrence J. Aldrich

Address on file with Company
  
	 	 	 	 	 	44,212	 	 	 	27,656	 	 
	 E. William Radany

Address on file with Company
  
	 	 	 	 	 	44,212	 	 	 	 	 	 
	 Bruce Seligmann

Address on file with Company
  
	 	143,661	 	 	 	 	 	 	 	 	 	 
	 ARCTURUS CAPITAL VENTURE FUND,

L.P.
 Address on file with Company

 
	 	 	 	 	 	1,445,087	 	1,108,156	 	 	 	 
	 The Second Sonenblick Family Limited

Partnership
 Address on file with Company

 
	 	 	 	32,915	 	72,254	 	 	 	 	 	 
	 Pete Clemens

Address on file with Company
  
	 	 	 	 	 	 	 	44,326	 	 	 	 
	 Weersing Family Trust

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	1,867,969	 	609,106
	 Bruce Seligmann, Trustee of the Seligmann-

Junghans Family Trust U/A/D July 9, 1999
 Address on file
with Company
  
	 	 	 	123,228	 	44,157	 	 	 	119,288	 	 
	 Timothy B. Johnson

Address on file with Company
  
	 	 	 	 	 	 	 	221,631	 	233,495	 	60,910
	 Constance Junghans

Address on file with Company
  
	 	 	 	 	 	44,212	 	 	 	119,288	 	 

													
	
NAME AND ADDRESS OF
  

STOCKHOLDER
	 	   SERIES  

 
 A
	 	  SERIES B  	 	   SERIES  

 
 C-1
	 	   SERIES  

 
 C-2
	 	  SERIES D  	 	  SERIES E  
	 Kirk Collamer

Address on file with Company
  
	 	 	 	 	 	44,212	 	 	 	119,288	 	 
	 BJ Kerns

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	23,857	 	 
	 John Luecke

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	11,928	 	 
	 Fredrick Pollock

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	4,771	 	 
	 Kathleen Toolan

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	119,288	 	 
	 Bernice Junghans

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	119,288	 	 
	 Sharyl Cummings & Steve Blomquist

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	119,288	 	 
	 Huw R. Jones and Cynthia D. Heydon-Jones

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	238,577	 	 
	 Douglas E. Marsh 401(k) Profit Sharing Plan

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	71,573	 	 
	 James Glinn

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	861,723	 	 
	 Basil E. Horner

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	23,857	 	 
	 Jerry Sonenblick

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	47,715	 	 
	 Edward Michael Gloyne

Address on file with Company
  
	 	 	 	164,577	 	148,341	 	 	 	238,577	 	 
	 Phillip Chu

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	119,288	 	 
	 John Wineman

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	91,366	 	 
	 Tom Vasicek

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	22,841	 	 

													
	
NAME AND ADDRESS OF
  

STOCKHOLDER
	 	   SERIES  

 
 A
	 	  SERIES B  	 	   SERIES  

 
 C-1
	 	   SERIES  

 
 C-2
	 	  SERIES D  	 	  SERIES E  
	 Danilo Cacciamatta

Address on file with Company
  
	 	 	 	100,964	 	 	 	 	 	 	 	 
	 DBD Fund, Inc.

Address on file with Company
  
	 	 	 	81,246	 	 	 	 	 	 	 	 
	 Deimos Ventures, LLC

Address on file with Company
  
	 	 	 	645,161	 	 	 	 	 	 	 	 
	 Holualoa Arizona, Inc.

Address on file with Company
  
	 	 	 	162,386	 	 	 	 	 	 	 	 
	 Margaret King Joukowsky

Address on file with Company
  
	 	 	 	36,895	 	 	 	 	 	 	 	 
	 William H. Lomicka

Address on file with Company
  
	 	 	 	81,069	 	 	 	 	 	 	 	 
	 Tucson Pharma Ventures, LLC

Address on file with Company
  
	 	 	 	32,555	 	 	 	 	 	 	 	 
	 Daniel D. Von Hoff, M.D.

Address on file with Company
  
	 	 	 	81,528	 	 	 	 	 	 	 	 
	 BSE Trust

Address on file with Company
  
	 	 	 	82,289	 	 	 	 	 	 	 	 
	 Fairfax Management Company, LLC

Address on file with Company
  
	 	 	 	65,831	 	 	 	 	 	 	 	 
	 Artemis Joukowsky III

Address on file with Company
  
	 	 	 	45,093	 	 	 	 	 	21,800	 	 
	 John Lubniewski

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	228,414	 	76,138
	 Shaun McMeans

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	114,207	 	152,276
	 Stephen Hagan

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	114,207	 	60,910
	 Debra Gordon

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	25,124	 	 
	 Julie Capadona

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	1,133	 	 
	 Elsie L. Elliott

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	20,954	 	 

													
	
NAME AND ADDRESS OF
  

STOCKHOLDER
	 	   SERIES  

 
 A
	 	  SERIES B  	 	   SERIES  

 
 C-1
	 	   SERIES  

 
 C-2
	 	  SERIES D  	 	  SERIES E  
	 Jeffrey R. Lee

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	764	 	 
	 Tamara Morrissy

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	52	 	 
	 Donald Ball

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	 	 	30,456
	 David and Shaila Silverio, JTWROS

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	 	 	60,910
	 Todd McMeans

Address on file with Company
  
	 	 	 	 	 	 	 	 	 	 	 	152,276
	 Desert Sidecar IV, LLC

c/o Curtis Gunn
 Address on file with Company

 
	 	 	 	 	 	 	 	 	 	 	 	102,786

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]